News | May 25, 2021
Orchid Pharma to transfer IKKT undertaking to JV with Bionpharma
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The company plans to enter the EU markets in FY22
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Dr. Reddy's has the rights to distribute 250mn doses in India
India sales grew 23.5% YoY with consolidation of Wockhardt products
Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Subscribe To Our Newsletter & Stay Updated
